Aceragen Inc Watch

from 8-K 4 pages Executive Separation Agreement

from 8-K 20 pages Security Agreement

from 8-K 36 pages Bridge Funding Agreement

from 8-K 8 pages Voting Agreement

from 10-K 3 pages Amendment No. 1 to Executive Transition and Separation Agreement

from 10-K 2 pages Amendment No. 1 to Executive Transition and Separation Agreement

from 10-K 5 pages Aceragen, Inc. ​ Nonqualified Stock Option Grant Agreement Granted Pursuant to the 2022 Equity Incentive Plan for Directors of the Company

from 10-K 5 pages Aceragen, Inc. ​ Nonqualified Stock Option Grant Agreement Granted Pursuant to the 2022 Equity Incentive Plan

from 10-K 6 pages Aceragen, Inc. ​ Incentive Stock Option Grant Agreement Granted Pursuant to the 2022 Equity Incentive Plan

from 8-K 20 pages The Purpose of the Plan Is to Provide Employees of Idera Pharmaceuticals, Inc., a Delaware Corporation (Together With Its Successors, the “Company”), and Its Subsidiaries, Certain Consultants and Advisors Who Perform Services for the Company or Its Subsidiaries, and Non-Employee Members of the Board of Directors of the Company, With the Opportunity to Receive Grants of Equity Awards in the Form of Incentive Stock Options, Nonqualified Stock Options, Stock Appreciation Rights, Stock Awards, Stock Units, and Other Stock-Based Awards. Capitalized Terms Used in the Plan and Not Therein Defined Shall Have the Meaning Assigned to Them in Section 2. the Company Believes That the Plan Will Encourage the Participants to Contribute Materially to the Growth of the Company, Thereby Benefitting the Company’s Stockholders, and Will Align the Economic Interests of the Participants With Those of the Stockholders. the Plan Is Intended to Replace the Prior Plan. No Additional Grants Shall Be Made Under the Prior Plan on or After the Effective Date. Outstanding Grants Under the Prior Plan Shall Continue in Effect According to Their Terms. Section 2. Definitions. the Following Terms Shall Have the Meanings Set Forth Below for Purposes of the Plan

from 10-Q 4 pages First Amendment to Stock Option Agreement

from 10-Q 47 pages Aceragen, Inc. 2021 Stock Incentive Plan

from 10-Q 4 pages ​ ​ ​ Project Agreement No.:01 ​ McDC Base Agreement No.:2021-479 ​ Project Title: McDc2104-001; Oral Regimen for Melioidosis Treatment and Post- Exposure Prophylaxis ​ Parties: Advanced Technology International (“McDC Cmf”) and Arrevus, Inc. (“Project Agreement Holder”) ​ This Project Agreement Is Awarded Under the Authority of McDC Other Transaction Agreement No. W15qkn-16-9-1002 and Herein Incorporates All the Terms and Conditions of McDC Base Agreement No. 2021-479. ​ 1. Payment Method the Payment Method for This Project Agreement Is Cost Plus Fixed Fee With a Not to Exceed Ceiling. ​ 2. Term of the Project Agreement the Period of Performance for This Project Agreement Is From the Effective Date, Which Is the Date of the Last Signature Through December 31, 2026. ​ 3. Obligation the McDC Cmf’s Liability to Make Payments to the Project Agreement Holder Is Limited to Only Those Funds Obligated Under This Project Agreement or by Modification to the Project Agreement. McDC Cmf May Incrementally Fund This Project Agreement. ​ 4. Estimated Cost and Fixed Fee the Total Estimated Cost and Fixed Fee for the Services to Be Provided by the Project Agreement Holder Is as Follows: ​ ​ Estimated Cost Estimated Cost $[***] Fixed Fee $[***] ​ ​ Total Cost $[***] ​ 5. Incremental Funding

from 10-Q 60 pages Base Agreement Between Advanced Technology International (Ati) 315 Sigma Drive Summerville, Sc 29486 and Arrevus, Inc. 2443 Lynn Rd, Suite 210 Raleigh, Nc 27612 Duns: 080059821

from 10-Q 11 pages Therapeutic Development Award Agreement

from 10-Q 38 pages Sales Distribution and Prv Agreement

from 10-Q 5 pages Amendment to Stock and Warrant Purchase Agreement

from 10-Q 55 pages Stock and Warrant Purchase Agreement

from 10-Q 11 pages Side Letter Agreement

from 8-K 6 pages Executive Transition and Separation Agreement